Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part I

Imagem de Miniatura
Arquivos
art_MELHADO_Consensus_of_the_Brazilian_Headache_Society_SBCe_for_2022.PDF (840.76 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2022
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC ARQUIVOS NEURO- PSIQUIATRIA
Autores
MELHADO, Eliana Meire
SANTOS, Paulo Sergio Faro
KAUP, Alexandre Ottoni
COSTA, Aline Turbino Neves Martins da
ROESLER, Celia Aparecida de Paula
PIOVESAN, Elcio Juliato
SARMENTO, Elder Machado
THEOTONIO, Giselle Oliveira Martins
CAMPOS, Henrique Carneiro de
Citação
ARQUIVOS DE NEURO-PSIQUIATRIA, v.80, n.8, p.845-861, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The Brazilian Headache Society (Sociedade Brasileira de Cefaleia, SBCe, in Portuguese) nominated a Committee of Authors with the aim of establishing a consensus with recommendations regarding prophylactic treatment for episodic migraine based on articles published in the worldwide literature, as well as personal experience. Migraine affects 1 billion people around the world and more than 30 million Brazilians. In addition, it is an underdiagnosed and undertreated disorder. It is well known within the medical community of neurologists, and especially among headache specialists, that there is a need to disseminate knowledge about prophylactic treatment for migraine. For this purpose, together with the need for drug updates and to expand knowledge of the disease itself (frequency, intensity, duration, impact and perhaps the progression of migraine), this Consensus was developed, following a full online methodology, by 12 groups who reviewed and wrote about the pharmacological categories of the drugs used and, at the end of the process, met to read and establish conclusions for this document. The drug classes studied were: anticonvulsants, tricyclic antidepressants, monoclonal anti-calcitonin gene-related peptide (anti-CGRP) antibodies, beta-blockers, antihypertensives, calcium channel inhibitors, other antidepressants (selective serotonin reuptake inhibitors, SSRIs, and dual-action antidepressants), other drugs, and polytherapy. Hormonal treatment and anti-inflammatories and triptans in minimum prophylaxis schemes (miniprophylaxis) will be covered in a specific chapter. The drug classes studied for part I of the Consensus were: anticonvulsants, tricyclic antidepressants, monoclonal anti-CGRP antibodies, and beta-blockers.
Palavras-chave
Migraine Disorders, Consensus, Preventive Medicine
URI
https://observatorio.fm.usp.br/handle/OPI/51733
Referências
  1. AHUJA GK, 1985, INDIAN J MED RES, V82, P263
  2. Alrashood S T, 2016, Profiles Drug Subst Excip Relat Methodol, V41, P133, DOI 10.1016/bs.podrm.2015.11.001
  3. ANDERSSON PG, 1983, CEPHALALGIA, V3, P207, DOI 10.1046/j.1468-2982.1983.0304207.x
  4. [Anonymous], 2015, Continuum (Minneap Minn), V21, P1169, DOI 10.1212/01.CON.0000470920.20859.fe
  5. Ashina M, 2020, CEPHALALGIA, V40, P241, DOI 10.1177/0333102420905132
  6. Ashtari F, 2008, ACTA NEUROL SCAND, V118, P301, DOI 10.1111/j.1600-0404.2008.01087.x
  7. Assarzadegan F, 2016, IRAN RED CRESCENT ME, V18, DOI 10.5812/ircmj.23768
  8. Barbanti P, 2011, NEUROL SCI, V32, pS111, DOI 10.1007/s10072-011-0526-3
  9. Beattie K, 2012, PROF DRUG SUB EXCIP, V37, P245, DOI 10.1016/B978-0-12-397220-0.00006-4
  10. Brandes JL, 2004, JAMA-J AM MED ASSOC, V291, P965, DOI 10.1001/jama.291.8.965
  11. Brighina F, 2006, CLIN NEUROPHARMACOL, V29, P338, DOI 10.1097/01.WNF.0000236766.08409.03
  12. Pessina AC, 2001, J CARDIOVASC PHARM, V38, pS33, DOI 10.1097/00005344-200112003-00006
  13. Pizza V., 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P31
  14. Pizzolato R, 2011, J HEADACHE PAIN, V12, P521, DOI 10.1007/s10194-011-0338-0
  15. Preuss CV., 2021, STATPEARLS
  16. Queiroz LP, 2009, CEPHALALGIA, V29, P642, DOI 10.1111/j.1468-2982.2008.01782.x
  17. Ramadan Nabih M, 2004, Curr Pain Headache Rep, V8, P91, DOI 10.1007/s11916-004-0022-z
  18. ROMPEL H, 1970, South African Medical Journal, V44, P75
  19. Schellenberg R, 2008, HEADACHE, V48, P118, DOI 10.1111/j.1526-4610.2007.00785.x
  20. Silberstein S, 2008, NEUROLOGY, V70, P548, DOI 10.1212/01.wnl.0000297551.27191.70
  21. Silberstein S, 2007, CEPHALALGIA, V27, P220, DOI 10.1111/j.1468-2982.2006.01275.x
  22. Silberstein SD, 2012, NEUROLOGY, V78, P1337, DOI 10.1212/WNL.0b013e3182535d20
  23. Silberstein SD, 2004, ARCH NEUROL-CHICAGO, V61, P490, DOI 10.1001/archneur.61.4.490
  24. Silberstein S, 2013, CEPHALALGIA, V33, P101, DOI 10.1177/0333102412466968
  25. Silberstein Stephen D., 1999, Headache, V39, P633, DOI 10.1046/j.1526-4610.1999.3909633.x
  26. SIMON D, 1975, EPILEPSIA, V16, P549, DOI 10.1111/j.1528-1157.1975.tb04738.x
  27. Siniatchkin M, 2007, CEPHALALGIA, V27, P1024, DOI 10.1111/j.1468-2982.2007.01377.x
  28. SJAASTAD O, 1972, ACTA NEUROL SCAND, V48, P124, DOI 10.1111/j.1600-0404.1972.tb07532.x
  29. Skljarevski V, 2018, CEPHALALGIA, V38, P1442, DOI 10.1177/0333102418779543
  30. SORENSEN KV, 1988, ACTA NEUROL SCAND, V78, P346, DOI 10.1111/j.1600-0404.1988.tb03667.x
  31. Stauffer VL, 2018, JAMA NEUROL, V75, P1080, DOI 10.1001/jamaneurol.2018.1212
  32. Steiner TJ, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0846-2
  33. Steiner TJ, 1997, CEPHALALGIA, V17, P109, DOI 10.1046/j.1468-2982.1997.1702109.x
  34. STEINER TJ, 1988, HEADACHE, V28, P15, DOI 10.1111/j.1365-2524.1988.hed2801015.x
  35. STELLAR S, 1984, JAMA-J AM MED ASSOC, V252, P2576
  36. STENSRUD P, 1979, HEADACHE, V19, P333, DOI 10.1111/j.1526-4610.1979.hed1906333.x
  37. STENSRUD P, 1980, UPSALA J MED SCI, P37
  38. SUDILOVSKY A, 1987, HEADACHE, V27, P421, DOI 10.1111/j.1526-4610.1987.hed2708421.x
  39. Tfelt-Hansen P, 2017, CNS DRUGS, V31, P389, DOI 10.1007/s40263-017-0430-3
  40. TFELTHANSEN P, 1984, ACTA NEUROL SCAND, V69, P1, DOI 10.1111/j.1600-0404.1984.tb07772.x
  41. Verma A, 2013, CLIN NEUROPHARMACOL, V36, P193, DOI 10.1097/WNF.0000000000000005
  42. Villani V, 2011, HEADACHE, V51, P287, DOI 10.1111/j.1526-4610.2010.01842.x
  43. Vos T., 2017, LANCET, V390, P1211, DOI [10.1016/S0140-6736(17)32154-2, DOI 10.1016/S0140-6736(17)32154-2]
  44. Walter S, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0476-1
  45. Wheless JW, 2007, NEUROTHERAPEUTICS, V4, P163, DOI 10.1016/j.nurt.2006.11.008
  46. Zain S, 2013, J PAK MED ASSOC, V63, P3
  47. Zanchetti A, 2004, BLOOD PRESSURE, V13, P17, DOI 10.1080/08038020410016548
  48. Burch R, 2019, CURR TREAT OPTION NE, V21, DOI 10.1007/s11940-019-0557-2
  49. Chan KYY, 2011, PHARMACOL THERAPEUT, V129, P332, DOI 10.1016/j.pharmthera.2010.12.001
  50. Chen WT, 2001, HEADACHE, V41, P823, DOI 10.1046/j.1526-4610.2001.01150.x
  51. Chung JY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/891348
  52. Comite AD Hoc da Sociedade Brasileira de Cefaleia, 2002, ARQ NEURO-PSIQUIAT, V60, P159
  53. Couch JR, 2011, HEADACHE, V51, P33, DOI 10.1111/j.1526-4610.2010.01800.x
  54. Cutrer FM, 1997, CEPHALALGIA, V17, P93, DOI 10.1046/j.1468-2982.1997.1702093.x
  55. D'Andrea G, 1999, CEPHALALGIA, V19, P64, DOI 10.1046/j.1468-2982.1999.1901064.x
  56. Danesh A, 2019, CURR TREAT OPTION NE, V21, DOI 10.1007/s11940-019-0556-3
  57. de Tommaso M, 2008, NEUROSCI LETT, V442, P81, DOI 10.1016/j.neulet.2008.06.076
  58. Diamond M, 2005, HEADACHE, V45, P1023, DOI 10.1111/j.1526-4610.2005.05183.x
  59. Diamond S, 2007, HEADACHE, V47, P355, DOI 10.1111/j.1526-4610.2006.00631.x
  60. Diener HC, 2004, J NEUROL, V251, P943, DOI 10.1007/s00415-004-0464-6
  61. Dodick DW, 2020, HEADACHE, V60, P2220, DOI 10.1111/head.14007
  62. Dodick DW, 2018, JAMA-J AM MED ASSOC, V319, P1999, DOI 10.1001/jama.2018.4853
  63. Dodick DW, 2018, CEPHALALGIA, V38, P1026, DOI 10.1177/0333102418759786
  64. Dodick DW, 2014, LANCET NEUROL, V13, P1100, DOI 10.1016/S1474-4422(14)70209-1
  65. Dodick DW, 2009, CLIN THER, V31, P542, DOI 10.1016/j.clinthera.2009.03.020
  66. Domingues RB, 2009, ARQ NEURO-PSIQUIAT, V67, P973, DOI 10.1590/S0004-282X2009000600002
  67. Drake ME, 2004, CLIN NEUROPHARMACOL, V27, P278, DOI 10.1097/01.wnf.0000150866.98887.77
  68. Edvinsson L, 2018, NAT REV NEUROL, V14, P338, DOI 10.1038/s41582-018-0003-1
  69. EKBOM K, 1972, HEADACHE, V12, P15, DOI 10.1111/j.1526-4610.1972.hed1201015.x
  70. Ferrari MD, 2019, LANCET, V394, P1030, DOI 10.1016/S0140-6736(19)31946-4
  71. FORSSMAN B, 1983, HEADACHE, V23, P188, DOI 10.1111/j.1526-4610.1983.hed2304188.x
  72. Fumagalli C, 2020, PHARMACOL RES, V151, DOI 10.1016/j.phrs.2019.104587
  73. Gallai V, 2003, J HEADACHE PAIN, V4, P92, DOI 10.1007/s10194-003-0043-8
  74. Ghose K, 2002, J HEADACHE PAIN, V3, P79, DOI [10.1007/s101940200022, DOI 10.1007/S101940200022]
  75. Goadsby PJ, 2017, NEW ENGL J MED, V377, P2123, DOI 10.1056/NEJMoa1705848
  76. Goncalves AL, 2016, J NEUROL NEUROSUR PS, V87, P1127, DOI 10.1136/jnnp-2016-313458
  77. Griffin CE, 2013, OCHSNER J, V13, P214
  78. Gupta P, 2007, HEADACHE, V47, P402, DOI 10.1111/j.1526-4610.2006.00599.x
  79. HERING R, 1992, CEPHALALGIA, V12, P81, DOI 10.1046/j.1468-2982.1992.1202081.x
  80. Hesami O, 2018, IRAN J PHARM RES, V17, P783
  81. Jackson JL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212785
  82. JENSEN R, 1994, NEUROLOGY, V44, P647, DOI 10.1212/WNL.44.4.647
  83. Jimenez-Hernandez MD, 2002, REV NEUROLOGIA, V35, P603, DOI 10.33588/rn.3507.2002113
  84. JOHANNSSON V, 1987, HEADACHE, V27, P372, DOI 10.1111/j.1526-4610.1987.hed2707372.x
  85. Kadian R., 2020, STATPEARLS
  86. KANGASNIEMI P, 1987, CEPHALALGIA, V7, P231, DOI 10.1046/j.1468-2982.1987.0704231.x
  87. KANGASNIEMI P, 1984, CEPHALALGIA, V4, P91, DOI 10.1046/j.1468-2982.1984.0402091.x
  88. Kowacs F., ARQ NEURO-PSIQUIAT, V77, P509, DOI [10.1590/0004-282x20190078, DOI 10.1590/0004-282X20190078]
  89. Kumar A., 2021, ALZHEIMER DIS
  90. Kuritzky A., 1987, CEPHALALGIA, V7, P457, DOI 10.1177/03331024870070S6203
  91. Lampl C, 2005, J NEUROL NEUROSUR PS, V76, P1730, DOI 10.1136/jnnp.2005.063750
  92. Lampl C, 1999, CEPHALALGIA, V19, P58, DOI 10.1046/j.1468-2982.1999.1901058.x
  93. LANGOHR HD, 1985, HEADACHE, V25, P107, DOI 10.1111/j.1526-4610.1985.hed2502107.x
  94. Linde M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010611
  95. Lyseng-Williamson KA, 2011, DRUGS, V71, P489, DOI 10.2165/11204490-000000000-00000
  96. Maizels M, 2010, HEADACHE, V50, P650, DOI 10.1111/j.1526-4610.2010.01633.x
  97. MATHEW NT, 1995, ARCH NEUROL-CHICAGO, V52, P281, DOI 10.1001/archneur.1995.00540270077022
  98. Mathew NT, 2001, HEADACHE, V41, P119, DOI 10.1046/j.1526-4610.2001.111006119.x
  99. Min JH, 2011, J NEUROL SCI, V305, P136, DOI 10.1016/j.jns.2011.02.020
  100. Mohammadianinejad SE, 2011, CLIN NEUROPHARMACOL, V34, P174, DOI 10.1097/WNF.0b013e318225140c
  101. Moreno RA, 1999, REV BRAS PSIQUIATR, V21, P24, DOI [10.1590/S1516-44461999000500006, DOI 10.1590/S1516-44461999000500006]
  102. Mulleners WM, 2015, CEPHALALGIA, V35, P51, DOI 10.1177/0333102414534325
  103. NOONE JF, 1980, J INT MED RES, V8, P49
  104. Olesen J, 2018, CEPHALALGIA, V38, P1, DOI 10.1177/0333102417738202
  105. Paemeleire K, 2018, CURR OPIN NEUROL, V31, P274, DOI 10.1097/WCO.0000000000000548
  106. PALFERMAN TG, 1983, BRIT J CLIN PRACT, V37, P28
  107. Pascual J, 2004, HEADACHE, V44, P1024, DOI 10.1111/j.1526-4610.2004.04198.x
  108. Patsalos PN, 2003, METHOD FIND EXP CLIN, V25, P123, DOI 10.1358/mf.2003.25.2.723686
  109. Perucca E, 1997, PHARMACOL RES, V35, P241, DOI 10.1006/phrs.1997.0124

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC